M7D (@DrM7d) header
M7D (@DrM7d) profile picture

YOU ARE ALPHA, YOU CONTROL AND Definitely U don’t need no one ☝️

Joined June 2012
Photo by M7D (@DrM7d)Photo by M7D (@DrM7d)Photo by M7D (@DrM7d)Photo by M7D (@DrM7d)Photo by M7D (@DrM7d)Photo by M7D (@DrM7d)Photo by M7D (@DrM7d)Photo by M7D (@DrM7d)Photo by M7D (@DrM7d)
Everyone a feminist until the titanic start sinking.
1
14
🚨 $LLY FOUNDAYO: DISASTROUS PHASE 3 RESULTS IN JAPAN. The numbers are brutal. Eli Lilly’s oral obesity drug is delivering roughly HALF the weight loss of $NVO’s oral semaglutide, while suffering massive treatment discontinuation at its highest dose. ATTAIN-J Phase 3 — 72 weeks, 36 mg: 🔴 Just 7.9% weight loss (treatment-regimen estimand). 🔴 33.3% discontinued treatment at the highest dose. ONE IN THREE patients! Versus 15% on placebo. 🔴 Only 58.8% achieved even 5% weight loss. 🔴 Increasing the dose from 12 mg to 36 mg actually produced WORSE average results: 8.7% vs 7.9%. Now compare that with $NVO’s oral semaglutide 50 mg in the East Asian OASIS 2 trial: 🟢 14.3% weight loss at 68 weeks. 🟢 84.3% achieved at least 5% weight loss. 🟢 Just 4.5% discontinued because of adverse events. These are separate trials, not a head-to-head comparison, but the contrast is extraordinary. Foundayo delivered only 55% of semaglutide’s reported weight-loss efficacy, despite using its highest tested dose. And the discontinuation numbers raise serious questions about long-term tolerability and commercial persistence. This is supposed to be Lilly’s next global oral obesity blockbuster? If these results are replicated across international populations, the commercial implications could be enormous. The narrative that Lilly will dominate the global oral obesity market deserves serious reconsideration. A major competitive warning for $LLY. A potentially significant opportunity for $NVO. $NVO $LLY $VKTX
22
24
13
233
62,624
PALANTIR JUST REPORTED EARNINGS *PALANTIR 2Q REV. $1.94B, EST. $1.81B ( BEAT ✅ ) *PALANTIR 2Q ADJ EPS 41C, EST. 35C ( BEAT ✅ ) *PALANTIR 2Q ADJ. EBITDA $1.20B, EST. $1.09B ( BEAT ✅ ) *PALANTIR SEES FY ADJ. OPER PROFIT $4.90B, EST. $4.51B ( BEAT ✅ ) $PLTR
33
38
8
615
82,046
Fierce Pharma updated its chart tracking $NVO ’s Oral Wegovy and $LLY ’s Foundayo prescriptions. It is still a thing of beauty for Novo Nordisk. #stocks #investing #obesity
6
7
105
5,755
+200 مليون غرامات على مصرف الراجحي في السنتين الماضية !!! أبرز الغرامات :- - مخالفة تعليمات البنك المركزي (الإشرافية) - مخالفة تعليمات البنك المركزي (الخاصة بحماية العملاء) مجموع مخالفات 2024: 67 مخالفة من البنك المركزي مجموع مخالفات 2025: 46 مخالفة من البنك المركزي أيضًا يوجد مخالفة من البلدية بسبب عدم تجديد رخص البلدية.
سهم مصرف الراجحي من أكثر الاسهم اللي طُلب مني اكتب عنها - سعر السهم: 66.30 ريال - رأس المال: 60,000,000,000 ريال - القيمة السوقية: 397,800,000,000 ريال - رمز السهم: 1120 لمحة عن أكبر مصرف إسلامي والأكبر في السعودية...
17
22
1
174
217,518
$NVO Novo Nordisk presented strong new data for the Wegovy pill. ✅Early responders (about 29% of users) lost 21.6% of body weight by week 64 ✅Even non-early-responders lost a meaningful 11.5% ✅77% of people with poor physical function saw significant improvement in mobility vs. 43% on placebo They also dropped a comparison against $LLY's Orforglipron: The Wegovy pill produced greater weight loss, and orforglipron users were about 14x more likely to quit due to GI side effects. (take this with a grain of salt as this is not H2H). In a patient preference survey, 84% preferred a treatment profile matching Wegovy pill. The headline trial result (OASIS 4) remains 17% average weight loss vs. 2.7% for placebo over 64 weeks.
8
14
6
194
38,230
$LULU Still at zero debt Price is at $169, ATH at $517 New CEO in now They still have ZERO DEBT I would be very surprised if the new CEO does not borrow to buy back shares
12
13
2
541
94,376
$NVO $LLY $HIMS 🚨 BREAKING: NOVO SAYS ITS GLP-1 PILL > LILLY'S PILL 84% OF PARTICIPANTS PREFERRED THE $NVO WEGOVY PILL COMPARED TO $LLY FOUNDAYO (ORFORGLIPRON) IN A PATIENT STUDY NOVO SAYS WEGOVY PILL 25MG SHOWED GREATER MEAN WEIGHT LOSS VS. ORFORGLIPRON 36MG IN POPULATION-ADJUSTED INDIRECT TREATMENT COMPARISON
14
31
14
486
81,743
#PRESS The US Food and Drug Administration (FDA) has approved the first and only once-weekly basal insulin treatment for adults with type 2 diabetes. This reduces the burden of daily basal insulin therapy by lowering the number of weekly injections from seven to one. Learn more in the Company Announcement here: novonordisk.com/news-and-med…
9
41
21
211
138,918
$CRSR performed pretty much as expected. Gaming components and systems margins rose from 18.10% to 30.20%. I am out of my position. My thesis was to buy as algos pushed the stock higher on the headline beat, then maybe management would mention supply constraints and the stock would come under pressure. Regardless, I'll take the win!
I have been researching $CRSR recently, mostly due to the strong trends for Fanatec. Additionally, search trends for their RAM products have been very strong and could contribute meaningfully to margins. The major risk, which led to tempered guidance for the category, remains supply, as they can't sell what they can't source. Importantly, memory was roughly 34% of Corsair's Q3 revenue. Gamer and Creator Peripherals Segment is a mixed bag and needs further work. Management Quote: "This adjustment assumes a conservative outlook for Q4, primarily to account for a tight DDR5 memory market and reflects the latest estimated customer spending patterns. While Corsair has a strong mitigation plan in place for memory availability, we believe it is prudent to temper expectations on the upside in this category." If the mitigation plans work and they are able to secure supply, Corsair could catch a bid here.
1
1
10
2,537
الهلال يتصدر قائمة الأندية السعودية من حيث صافي الإنفاق السلبي خلال 10 فترات انتقال حيث بلغ 700 مليون يورو. (مرصد CIES للدراسات الرياضية) -
972
1,903
240
4,965
1,655,049
$NVO 's Oral Wegovy is taking off in the U.S. New prescriptions jumped from 4,289 → 20,371 in the first two weeks after launch. For comparison (week 2): • Wegovy injection: 1,017 • Zepbound (Eli Lilly): 10,026 Insured patients only. #StocksInFocus #investing
38
51
24
560
155,461
هل يحق للبنك الازرق الحاق الضرر بالعملاء ؟
1,129
631
44
3,940
716,555
⚖ الحالات التحكيمية لـ #نيوم_الهلال: -لا وجود لمخالفة على لاعب الهلال، الاستمرار قرار صحيح د45+3 -ركلة جزاء صحيحة للهلال د64 -كان يجب طرد لاعب نيوم لمنع فرصة تسجيل هدف د67 -ركلتا جزاء لم تحتسبتان لنيوم د82 و89 @Abo_zyad_q #دورينا_غير #قناة_السعودية
290
653
65
1,184
860,321
Tell me $HIMS is COOKed without telling me they're COOKed... 🔥
107
54
23
1,872
943,198
$AMZN Pharmacy is now offering $NVO Wegovy with home delivery across all 50 states. The move expands nationwide access to GLP-1 obesity treatment through Amazon’s pharmacy platform.
46
65
12
718
61,312
#PRESS The first GLP-1 pill for the treatment of obesity is now broadly available across America. Learn more in the press release here: novonordisk.com/content/nnco…
16
71
37
389
45,407
💊 حبوب ويغوفي (Wegovy) لإنقاص الوزن خبر مبشّر لمرضى السمنة 👇 🔹 أول دواء GLP-1 فموي معتمد لعلاج السمنة في أمريكا 🔹 يحقق نزول وزن بمتوسط حوالي 16% 🔹 يساعد على الحفاظ على الوزن وله فوائد قلبية ❤️ ⚠️ يُستخدم تحت إشراف الطبيب وليس بديلًا عن نمط الحياة الصحي. ✨ الأمل كبير… وكل يوم يظهر علاج جديد والخيارات الطبية للسمنة في تطوّر مستمر 🌱
6
28
121
11,670
تحول تاريخي في إنقاص الوزن.. أمريكا تُجيز أول أقراص من علاج Wegovy لإنقاص الوزن، ومن المتوقع طرح الأقراص في الأسواق بداية عام 2026. -
69
187
12
1,427
585,865
دراسة حديثة: تقليص العمل 4 أيام في الأسبوع حسّن الصحة النفسية وقلّل الإرهاق، دون انخفاض في الإنتاجية. (جامعة بوسطن)
249
405
69
2,000
376,512
#PRESS The first GLP-1 pill for the treatment of obesity is now approved by the US Food and Drug Administration (FDA). Learn more in our company announcement here: novonordisk.com/content/nnco…
62
225
70
1,013
154,584